Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Cavanagh Jamie, MD, Honorata Giongco Baylon, MD, Priscilla B. Caguioa, MD, Faith E. Davies, MD, Mecide Gharibo, MD, Shiro Akinaga, PhD, Michael R. Kurman, MD, Barbara A. Novak, BS, Kwee L. Yong, PhD

Blood (2013) 122 (21): 1967.

https://doi.org/10.1182/blood.V122.21.1967.1967

Published: 2013

Journal Articles

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma

Takashi Ishida, MD, PhD, Michinori Ogura, MD, PhD, Kiyohiko Hatake, Masafumi Taniwaki, MD, PhD, Kiyoshi Ando, MD, PhD, Kensei Tobinai, MD, PhD, Katsuya Fujimoto, MD, PhD, Kazuhito Yamamoto, M.D., Ph.D., Toshihiro Miyamoto, MD, PhD, Naokuni Uike, MD, PhD, Mitsune Tanimoto, MD, PhD, Kunihiro Tsukasaki, MD, PhD, Kenichi Ishizawa, MD, PhD, Junji Suzumiya, MD, PhD, Hiroshi Inagaki, MD, PhD, Kazuo Tamura, MD, PhD, Shiro Akinaga, PhD, Masao Tomonaga, MD, PhD, Ryuzo Ueda, MD, PhD

Blood (2012) 120 (21): 795.

https://doi.org/10.1182/blood.V120.21.795.795

Published: 2012

Journal Articles

Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results.

Kazuhito Yamamoto, MD, PhD, Kensei Tobinai, MD, PhD, Atae Utsunomiya, MD, Kunihiro Tsukasaki, MD, PhD, Naokuni Uike, MD, PhD, Kimiharu Uozumi, MD, Masao Tomonaga, MD, Koji Matsushima, MD, PhD, Kenya Shitara, PhD, Shiro Akinaga, PhD, Ryuzo Ueda, MD, PhD

Blood (2008) 112 (11): 1007.

https://doi.org/10.1182/blood.V112.11.1007.1007

Published: 2008

Journal Articles

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

Jorge Cortes, MD, Gail J. Roboz, MD, Hagop M. Kantarjian, Eric J. Feldman, MD, Judith E. Karp, MD, Keith W. Pratz, MD, Niranjan S. Rao, PhD, Shiro Akinaga, PhD, Mark J. Levis, MD, PhD

Blood (2008) 112 (11): 2967.

https://doi.org/10.1182/blood.V112.11.2967.2967

Published: 2008

Journal Articles

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

Yukimasa Shiotsu, PhD, Hitoshi Kiyoi, MD, PhD, Ryohei Tanizaki, MD, PhD, Yosuke Minami, MD, PhD, Akihiro Abe, MD, PhD, Yuichi Ishikawa, MD, PhD, Kenichi Ishii, Makiko Shimizu, Yutaka Kanda, PhD, Yuko Sato, MD, PhD, Shiro Akinaga, PhD, Jorge Cortes, MD, Tomoki Naoe, MD, PhD

Blood (2008) 112 (11): 1640.

https://doi.org/10.1182/blood.V112.11.1640.1640

Published: 2008

Journal Articles

KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo .

Yukimasa Shiotsu, PhD, Hitoshi Kiyoi, MD, PhD, Kazutaka Ozeki, MD, PhD, Hiroshi Umehara, Makiko Shimizu, Shiro Akinaga, PhD, Tomoki Naoe, MD, PhD

Blood (2007) 110 (11): 1832.

https://doi.org/10.1182/blood.V110.11.1832.1832

Published: 2007

NARROW

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma

Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results.

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo .

Email alerts

ASH Publications

American Society of Hematology

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CCR4 Antibody, in Patients with Relapsed Peripheral and Cutaneous T-Cell Lymphoma

Phase I Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, in Relapsed Patients (Pts) with Adult T-Cell Leukemia-Lymphoma (ATL) or Peripheral T-Cell Lymphoma (PTCL): Updated Results.

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo .

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only